Floatz logo

FILGRASTIM-SNDZ

Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1

M.D. Anderson Cancer Centerprotein_peptidePhase 2Active
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
31/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1 cohort.

Asset / SponsorPhaseRating
Sorafenib
National Cancer Institute (NCI)
Phase 2B
Cytosin-Arabinosid
National Cancer Institute (NCI)
Phase 2B
Daunorubicin
National Cancer Institute (NCI)
Phase 2B
Decitabine
M.D. Anderson Cancer Center
Phase 2CCC
Fludarabine
M.D. Anderson Cancer Center
Phase 2CCC
Idarubicine
M.D. Anderson Cancer Center
Phase 2CCC
Gemtuzumab Ozogamicin
M.D. Anderson Cancer Center
Phase 2CCC

Same molecule, other indications

FILGRASTIM-SNDZ is also rated in:

acute myeloid leukemiaDormant
CCC
Indicative ·
50 / 100
View asset →
B-cell acute lymphoblastic leukemiaDormant
CCC
Indicative ·
49 / 100
View asset →
acute leukemiaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →